Press Release

NeoGenomics Schedules its First Quarter 2022 Earnings Release for April 27, 2022

NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR™ Assay in Non-Small Cell Lung Cancer

NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences

NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021

NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific Officer

NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma

NeoGenomics to Participate Virtually in Multiple Upcoming Institutional Investor Conferences

NeoGenomics Schedules its Fourth Quarter and Full Year 2021 Earnings Release for February 23, 2022

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients